Search

Author/Creator van Cleeff, Martin

1. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Issue 19 (27th April 2016)

Authors:
de Bruyn, Guy; Saleh, Jamshid; Workman, David; Pollak, Richard; Elinoff, Victor; Fraser, Neil J.; Lefebvre, Gigi; Martens, Mark; Mills, Richard E.; Nathan, Richard; Trevino, Miguel; van Cleeff, Martin; Foglia, Ginamarie; Ozol-Godfrey, Ayca; Patel, Dhaval M.; Pietrobon, Patricia J.; Gesser, Richard
Journal:
Vaccine
Issue:
Volume 34:Issue 19(2016)
Page Start:
2170
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Issue 30 (24th June 2016)

Authors:
Frenck, Robert W.; Fiquet, Anne; Gurtman, Alejandra; van Cleeff, Martin; Davis, Matthew; Rubino, John; Smith, William; Sundaraiyer, Vani; Sidhu, Mohinder; Emini, Emilio A.; Gruber, William C.; Scott, Daniel A.; Schmoele-Thoma, Beate
Journal:
Vaccine
Issue:
Volume 34:Issue 30(2016)
Page Start:
3454
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Issue 3 (4th March 2019)

Authors:
Schmoele-Thoma, Beate; van Cleeff, Martin; Greenberg, Richard N.; Gurtman, Alejandra; Jones, Thomas R.; Sundaraiyer, Vani; Gruber, William C.; Scott, Daniel A.
Journal:
Human vaccines & immunotherapeutics
Issue:
Volume 15:Issue 3(2019)
Page Start:
575
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗